Vor Bio Secures $75M Ahead of Pivotal Trial
Vor Bio strengthened its financial position on March 27, 2026, by securing approximately $75 million through a private placement. The deal involved the sale of 5,338,078 shares of common stock at a price of $14.05 per share to a group led by new investor TCGX. The company stated the proceeds will fund the clinical development of telitacicept, including its global Phase 3 trials for primary Sjögren’s disease and myasthenia gravis, two conditions representing large, multi-billion-dollar opportunities.
Our investment reflects the conviction we have in the Vor Bio team and the disruptive potential of telitacicept.
— Cariad Chester, Managing Partner at TCGX.
Phase 3 Trial Begins for First-in-Class Sjögren's Drug
Just days after the financing, Vor Bio announced on March 30 that it had dosed the first patient in its global Phase 3 UPSTREAM SjD trial. The study will evaluate telitacicept in approximately 250 adult patients with primary Sjögren’s disease, a chronic autoimmune condition with no approved disease-modifying treatments. The primary endpoint is the change in disease activity score at Week 48. Confidence for the trial is partly based on a successful Phase 3 study conducted in China by RemeGen in late 2025, which showed statistically significant improvements in key disease measurements.
Telitacicept is a novel fusion protein that targets two key drivers of autoimmune disease, BLyS (BAFF) and APRIL, and is the only dual inhibitor in Phase 3 development for this condition. Its progress marks a critical step toward potentially offering the first systemic therapy for a disease that is often underdiagnosed and primarily affects women. The drug is already approved in China for other autoimmune diseases, including systemic lupus erythematosus and rheumatoid arthritis, providing a foundation of safety and efficacy data.
